A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-12. Anything still debated is marked as such rather than presented as settled.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
does not give credibility to the report and asserting that the Iranian regime is the only party committing war crimes in the conflict. The U.S. Central Command (CENTCOM) previously denied responsibility for the strike in Lamerd and stated it was investigating the incident in Minab.
Martín-Francés et al. (2026) interpret the molar wear in the Sima de los Huesos hominins as suggestive of a mixed diet including similar proportions of meat and plant foods. Parfitt & Bello (2026) describe a 480,000-years-old knapping tool made on an elephant bone from the Boxgrove Palaeolithic site (United Kingdom), representing the oldest case of an elephant bone being used as a raw material in Europe reported to date. Nicoud et al. (2026) study the chronology of bifacial occurrences from Valle Giumentina (Italy), reporting evidence of shifts in the biface structure within two levels from Marine Isotope Stage 12, and interpret evidence from the studied site as consistent with repeated reinventions of the biface in Europe during the Lower Paleolithic. A study on the Acheulean handaxe variability in southeastern Britain, interpreted as consistent with presence of distinct regional cultural groups during the Marine Isotope Stage 11, is published by White et al. (2026). García-Martínez et al. (2026) provide the first proteomics-based sex identification of a hominin tooth from the Middle Pleistocene of western Europe, using the analysis of the presence of amelogenin to attribute a hominin molar from the Middle Pleistocene site of Ruidera (Spain) to a male individual. Rosas et al.
Control of petroleum production has been a significant driver of international relations during much of the 20th and 21st centuries. Organizations like OPEC have played an outsized role in international politics. Some historians and commentators have called this the "Age of Oil" With the rise of renewable energy and addressing climate change some commentators expect a realignment of international power away from petrostates.
Sources: en.wikipedia.org
A 58-hour curfew was announced in Kherson. Oleksandr Prokudin, the Ukrainian governor of Kherson Oblast, said that during the curfew: "it is forbidden to move on the streets of the city. The city will also be closed for entry and exit". Twenty-four civilians were killed in Kherson city due to Russian shelling. Russia said it had shot down two drones over the Moscow Kremlin and accused Ukraine of sending them to assassinate President Vladimir Putin. The Institute for the Study of War commented that it was "extremely unlikely that two drones could have penetrated multiple layers of air defence and detonated or been shot down just over the heart of the Kremlin in a way that provided spectacular imagery caught nicely on camera". The Ukrainian government denied the accusations, calling them fabricated. The British Ministry of Defence reported that several unmanned aerial vehicles (UAVs) struck Russia's Seshcha Airbase in Bryansk Oblast, 150 km north of the Ukrainian border, adding that an An-124 heavy transport aircraft was likely damaged.
=== Heart and vascular === The SOMC Heart Care Unit is a 12-bed unit responsible for the care of adult cardiac patients and patients recovering from open heart surgery. SOMC utilizes a Universal Bed Model, in which the patient's room essentially changes throughout the open-heart procedure, starting as an intensive care recovery room on arrival from surgery and transitioning to a home-like environment with family space and amenities. Heart and Vascular services provided at SOMC include:
The success of "Upside Down" led to interest from WEA-subsidiary Blanco y Negro Records which signed the group in early 1985. The group released the single "Never Understand" in February which reached number forty-seven on the UK Singles Chart. The label had initially refused to press the single due to its B-side, "Suck", but went ahead given the alternative put forward by the band, a song called "Jesus Fuck". The band were eager to get "Jesus Fuck" released, and McGee got as far as producing test pressings of a re-issue of "Upside Down" with the song on the B-side, before the band insisted that Blanco y Negro include the track on their next single. The follow-up, "You Trip Me Up", was delayed due to staff at the pressing plant refusing to press it due to the presence of the song, now re-titled "Jesus Suck"; The single was released in June 1985 with a new B-side, "Just Out of Reach". John Peel got the band to record a second session for his BBC Radio 1 show in February 1985 (the first was only a few months earlier), and the band also made a TV appearance on Whistle Test in March and The Tube the same year. The third single for Blanco y Negro, "Just Like Honey", released in October, was their biggest hit to date, reaching No. 45. Eager to avoid the violence of earlier gigs and to give an opportunity for their songs to be heard without distortion and feedback, the band planned to perform several unannounced acoustic sets supporting Sonic Youth, but this was abandoned when the plans were leaked. Their debut album, Psychocandy, followed in November that year.
=== In plants === In plants, glutathione plays a role in stress response. It is a component of the glutathione-ascorbate cycle, a system that reduces poisonous hydrogen peroxide. It is the precursor of phytochelatins, glutathione oligomers that chelate heavy metals such as cadmium. Glutathione is required for efficient defense against plant pathogens such as Pseudomonas syringae and Phytophthora brassicae. Adenylyl-sulfate reductase, an enzyme of the sulfur assimilation pathway, uses glutathione as an electron donor. Other enzymes using glutathione as a substrate are glutaredoxins. These small oxidoreductases are involved in flower development, salicylic acid, and plant defense signalling.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.